Some medications could have the unintended benefit of reducing dementia risk. That’s according to a recent study by the universities of Cambridge and Exeter, where researchers evaluated several ...

A major review has provoked a backlash after concluding the medicines provide too little benefit to be noticed.

Multiple clinical trials have shown that GLP-1s are safe and effective for patients with obesity, diabetes and cardiovascular ...

Drugs designed to clear amyloid beta from the brain—once seen as a promising path to slowing Alzheimer’s—may not actually ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

Getting yourself vaccinated against shingles doesn’t just protect you against that painful and debilitating disease — it may also slash your risk of developing Alzheimer’s by as much as 20%, according ...

A major review has found that new Alzheimer's drugs hailed as breakthroughs may offer only limited benefits for patients. Treatments including donanemab and lecanemab have been shown in clinical ...

A new review of clinical trial data finds evidence that GLP-1 drugs can meaningfully reduce dementia risk in people with type 2 diabetes. Reading time 2 minutes The case for Ozempic as a dementia ...

An extensive review of Alzheimer's drugs that have been considered ground-breaking for treatment revealed that they actually have little effect on patients. This disappointing verdict stems from a ...

Getting yourself vaccinated against shingles doesn't just protect you against that painful and debilitating disease - it may also slash your risk of developing Alzheimer's by as much as 20%, according ...